↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Nahi H) ;pers:(Bahlis NJ)"

Search: WFRF:(Nahi H) > Bahlis NJ

Result 1-10 of 24

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Facon, T, et al. (author) Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis 2022 In: BLOOD. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 140, s. 10133-10136 Conference paper (other academic/artistic)
2.	Facon, T, et al. (author) Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA 2022 In: Leukemia. - : Springer Science and Business Media LLC. - 1476-5551 .- 0887-6924. ; 36:4, s. 1066-1077 Journal article (peer-reviewed)abstract In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd). We present a subgroup analysis of MAIA by frailty status. Frailty assessment was performed retrospectively using age, Charlson comorbidity index, and baseline Eastern Cooperative Oncology Group performance status score. Patients were classified as fit, intermediate, non-frail (fit + intermediate), or frail. Of the randomized patients (D-Rd, n = 368; Rd, n = 369), 396 patients were non-frail (D-Rd, 196 [53.3%]; Rd, 200 [54.2%]) and 341 patients were frail (172 [46.7%]; 169 [45.8%]). After a 36.4-month median follow-up, non-frail patients had longer PFS than frail patients, but the PFS benefit of D-Rd versus Rd was maintained across subgroups: non-frail (median, not reached [NR] vs 41.7 months; hazard ratio [HR], 0.48; P < 0.0001) and frail (NR vs 30.4 months; HR, 0.62; P = 0.003). Improved rates of complete response or better and minimal residual disease (10–5) negativity were observed for D-Rd across subgroups. The most common grade 3/4 treatment-emergent adverse event in non-frail and frail patients was neutropenia (non-frail, 45.4% [D-Rd] and 37.2% [Rd]; frail, 57.7% and 33.1%). These findings support the clinical benefit of D-Rd in transplant-ineligible NDMM patients enrolled in MAIA, regardless of frailty status.
3.	Kumar, SK, et al. (author) Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study 2022 In: BLOOD. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 140, s. 10150-10153 Conference paper (other academic/artistic)
4.	Moreau, P, et al. (author) Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study 2022 In: BLOOD. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 140, s. 7297-7300 Conference paper (other academic/artistic)
5.	Bahlis, NJ, et al. (author) Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial 2017 In: Leukemia. - : Springer Science and Business Media LLC. - 1476-5551 .- 0887-6924. ; 31:11, s. 2435-2442 Journal article (peer-reviewed)
6.	Bahlis, NJ, et al. (author) Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX). 2017 In: JOURNAL OF CLINICAL ONCOLOGY. - 0732-183X. ; 35 Conference paper (other academic/artistic)
7.	Bahlis, NJ, et al. (author) Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial 2014 In: BLOOD. - 0006-4971. ; 124:21 Conference paper (other academic/artistic)
8.	Dimopoulos, MA, et al. (author) Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma 2016 In: The New England journal of medicine. - 1533-4406. ; 375:14, s. 1319-1331 Journal article (peer-reviewed)
9.	Dimopoulos, MA, et al. (author) EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED ANALYSIS OF POLLUX 2017 In: HAEMATOLOGICA. - 0390-6078. ; 102, s. 108-109 Conference paper (other academic/artistic)
10.	Dimopoulos, MA, et al. (author) Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial 2023 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 1527-7755. ; 41:8, s. 1590-1599 Journal article (peer-reviewed)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-10 of 24

Refine your search

Type of publication: conference paper (14); journal article (10)

Type of content: other academic/artistic (14); peer-reviewed (10)

Author/Editor: Nahi, H (24); Bahlis, NJ (24)Undo refine; Plesner, T (14); Usmani, SZ (14); Moreau, P (12); Orlowski, RZ (11); show more...; Hulin, C (11); Qin, X. (10); Goldschmidt, H (10); Facon, T (9); Richardson, PG (9); Ahmadi, T (7); Weisel, K (7); Usmani, S (7); Qi, M. (6); Basu, S (6); Suzuki, K. (6); Rabin, N (6); Oriol, A (6); Perrot, A (6); Mateos, MV (6); Chari, A (5); Pei, HL (5); Dimopoulos, MA (5); White, D. (4); Yoon, SS (4); Reece, D. (4); Chiu, C (4); San-Miguel, J (4); Quach, H (4); Kumar, SK (4); Venner, CP (4); Raje, N (4); Borgsten, F (4); Cavo, M (4); Grosicki, S (4); Hungria, V (4); Kumar, S (3); Delforge, M (3); Frenzel, L (3); Decaux, O (3); O'Dwyer, M (3); Tiab, M (3); Macro, M (3); Leleu, X (3); Blade, J (3); Roussel, M (3); Spicka, I (3); Lonial, S (3); Ben Yehuda, D (3); show less...

University: Karolinska Institutet (24)

Language: English (24)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view